Women who were 40 years of age on January 1st and 64 years of age on December 31st of each year were extracted. Recipients with a diagnosis of breast cancer or abnormal breast fi ndings were excluded from the analyses using appropriate ICD-9 codes (174. XX, 233.0X, 238.3X, 239.3X). Data for women with claims for screening mammography at any time during each calendar year were extracted using following CPT code: 76092. Results were reported by age group (40-49 years, 50-59 years, and 60-64 years), race (White, Black, and others), county of residence, and geographic area (metro, non-metro urban, non-metro rural) for each calendar year. RESULTS: There was an estimated 12% increase in the screening mammography between 2000 and 2005. A consistent increase in the mammography screening was observed during study period (2000)(2001)(2002)(2003)(2004)(2005) among women who were 50-59 years of age as compared to those between 40-49 and 60-64 years of age. Approximately 90% women who underwent screening mammography resided in either metro or non-metro urban areas. CONCLUSIONS: Screening mammography trends differed among women based on demographic characteristics. Further research is needed to evaluate accessibility and knowledge among indigent women in order to develop effective breast cancer prevention strategies.
PCN105 GUIDELINES AND CANCER SCREENING IN THE UNITED STATES AND CANADIAN HEALTH SYSTEMS
Kadiyala S y 1 , Strumpf EC 2 1 University of Washington, Seattle, WA, USA, 2 McGill University, Monreal, QC, Canada OBJECTIVES: To understand Canadian and U.S. health system compliance with cancer screening guideline information with respect to the age of screening initiation. METHODS: Canadian and U.S. cancer screening generally identify ages when cancer screening should be initiated. We use a regression discontinuity research design to identify discrete increases in Canadian and U.S. cancer screenings in the past two years at the guideline recommended ages. Multivariate logistic regression analyses were performed using breast, prostate and colorectal cancer screening within the past two years as the dependent variables of interest. Logistic regression models also adjust for respondent demographic and socioeconomic characteristics. We analyze screening for adult individuals from the 2006 Behavioral Risk Factor Social Survey, 2003 National Health Interview and 2003 and 2005 Canadian Community Health Surveys. RESULTS: Graphical and logistic regression analyses identifi ed large statistically signifi cant increases in cancer screening rates precisely at the U.S. guideline recommended screening initiation ages. U.S. breast, colorectal and prostate screenings increase by 33%, 33% and 25% precisely at the guideline recommended ages(age 40 for breast and age 50 for colorectal and prostate cancers). Similarly in Canada we found a 20% increase in breast cancer screening at age 50, the Canadian guideline recommended age for screening initiation. We did not fi nd a discrete increase in the Canadian colorectal cancer screening rate at the Canadian recommended screening age of 50. CONCLUSIONS: U.S. and Canadian cancer screening utilization is generally consistent with each country's guideline recommendations regarding age. The cross-country differences in screening identifi ed in this study can potentially explain cross-country differences in cancer mortality rates and affect interpretation of crosscountry cancer statistics. The similarity of other OECD cancer screening guidelines to Canadian screening guidelines suggests that results from this study have broader applicability to comparisons of cancer statistics between U.S. and other OECD countries.
P.CN106 THE IMPACT OF CANCER SCREENING GUIDELINE INFORMATION ON CANCER DETECTION
Kadiyala S y 1 , Strumpf EC 2 1 University of Washington, Seattle, WA, USA, 2 McGill University, Monreal, QC, Canada OBJECTIVES: To understand the impact of U.S. cancer screening guideline information on U.S. cancer screening and cancer detection. METHODS: We use an instrumental variables research design to identify the effects of breast, colorectal and prostate cancer screening guideline information on cancer detection. U.S. guidelines specify an age at which screening should begin, implicitly recommending that screening not occur for asymptomatic individuals below that age. We fi rst estimate compliance with guideline information from the difference in age-specifi c screening rates just below and above the ages at which clinical guidelines recommend that screening begin. We then perform instrumental variables regression analyses to estimate the effect of guideline induced screening on cancer detection. U.S. cancer screening and incidence data (years 2000-2005) are derived from the Behavioral Risk Factor Social Survey, the National Health Interview Survey and the SEER Program. RESULTS: Age-specifi c screening rates from national BRFSS and NHIS survey data indicate that U.S. breast, colorectal and prostate cancer screening in the last year rise by 55%, 88% and 29% precisely at the guideline recommended ages(age 40 for breast cancer and age 50 for colorectal and prostate cancers). Results from instrumental variables analyses indicate that a 1% point increase in screening at the guideline recommended ages leads to an additional case of breast and colorectal cancer detected per 100,000 individuals. The substantial increase in prostate cancer screening did not have an identifi able effect on prostate cancer detection. CONCLUSIONS: We used an instrumental variables strategy to identify the impact of guideline information on cancer screening and detection. Guideline information induces substantial increases in breast, colorectal and prostate cancer screening but these changes only lead to increases in breast and colorectal cancer detection. These results suggest that reductions in the use of the PSA test will result in substantial cost savings with minimal reductions in health.
PCN108 IMPACT OF NEW DRUGS AND BIOLOGICALS ON TREATMENT AND COSTS FOR COLORECTAL CANCER
Shah ND 1 , Van Houten H 1 , Vermeulen L 2 1 Mayo Clinic, Rochester, MN, USA, 2 University of Wisconsin Hospital and Clinics, Madison, WI, USA OBJECTIVES: There have been a number of new drugs and biologicals approved by the FDA in the last fi ve-years for the treatment of colorectal cancer (CRC). Objective of this study was to compare the initial treatments and overall medical costs for working-age persons with CRC before and after the introduction of these treatments. METHODS: This retrospective cohort study was based on a large administrative database and included patients with an ICD-9 diagnosis of CRC. We looked at individuals treated for CRC in the period prior to introduction of new chemotherapy and biological agents (January 2002 -December 2002 and the period after the introduction of two biologicals (bevacizumab and cetuximab) and one chemotherapy agent (oxaliplatin), (June 2004 -May 2005 . We assigned patients to stage of diagnosis based on treatment regimens. We identifi ed 2545 patients (61% Stage III) with CRC in the pre-period and 4413 patients (59% Stage III) with CRC in the post-period. We estimated mean total medical costs in the pre-and post-periods using the Kaplan-Meier sample average estimator. RESULTS: The predominant treatment regimen in the pre-period for stage III CRC was 5-FU/Leucovorin (77%), while the pre-dominant regimens the post-period were 5-FU/Leucovorin (36%) and FOLFOX (35%). The pre-dominant treatment regimen for stage IV CRC was IFL/FOLFIRI (50%), while the most common regiments in the post-period were IFL/FOLFIRI (22%) and FOLFOX (23%). Additionally, over 14% of the patients received a biological agent in the post-period. There was also a signifi cant increase in total medical costs over this time period. The mean costs for Stage III and Stage IV CRC patients increased from $56,187 in the pre-period to $101,049 in the post-period (p 0.001). CONCLU-SIONS: The introduction of new treatments for CRC signifi cantly changed the treatment patterns for both Stage III and Stage IV CRC. These changes in treatment were accompanied by a signifi cant increase total medical costs.
